Wu Linghong, Zhu Ying
Department of Infectious Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Int J Mol Med. 2015 Nov;36(5):1200-4. doi: 10.3892/ijmm.2015.2337. Epub 2015 Sep 2.
The lysyl oxidase (LOX) family is comprised of five members, and some members have recently emerged as important regulators of tumor progression. Among these, at present, LOX‑like (LOXL)2 is the prototypical LOX and the most comprehensively studied member. A growing body of evidence has implicated LOXL2 in the promotion of cancer cell invasion, metastasis and angiogenesis, as well as in the malignant transformation of solid tumors. Moreover, a high expression of LOXL2 is associated with a poor prognosis. These data have piqued the interest of a number of researchers and research groups, who have identified LOXL2 as a strong target candidate in the development of inhibitors for use as functional and efficacious tumor therapeutics. In the present study, we summarize the recent progress made regarding LOXL2, mainly focusing on its function and mechanisms of action in tumor progression and metastasis. In this review, we note that LOXL2 promotes tumor progression possibly by activating multiple signal pathways through a variety of mechanisms, both biochemical and biomechanical. The data presented herein may open new avenues for the therapeutic utility of LOXL2.
赖氨酰氧化酶（LOX）家族由五个成员组成，最近一些成员已成为肿瘤进展的重要调节因子。其中，目前，类赖氨酰氧化酶（LOXL）2是典型的LOX，也是研究最为全面的成员。越来越多的证据表明，LOXL2在促进癌细胞侵袭、转移和血管生成以及实体瘤的恶性转化中发挥作用。此外，LOXL2的高表达与预后不良相关。这些数据引起了许多研究人员和研究团队的兴趣，他们已将LOXL2确定为开发用作功能性和有效肿瘤治疗药物的抑制剂的强大候选靶点。在本研究中，我们总结了关于LOXL2的最新进展，主要关注其在肿瘤进展和转移中的功能及作用机制。在本综述中，我们指出，LOXL2可能通过多种生化和生物力学机制激活多个信号通路来促进肿瘤进展。本文提供的数据可能为LOXL2的治疗应用开辟新途径。
